Plasma Cannabinoid Concentrations During Dronabinol Pharmacotherapy for Cannabis Dependence

被引:16
|
作者
Milman, Garry [1 ]
Bergamaschi, Mateus M. [1 ]
Lee, Dayong [1 ]
Mendu, Damodara R. [1 ]
Barnes, Allan J. [1 ]
Vandrey, Ryan [2 ]
Huestis, Marilyn A. [1 ]
机构
[1] NIDA, Chem & Drug Metab Sect, Intramural Res Program, Biomed Res Ctr,NIH, Baltimore, MD 21224 USA
[2] Johns Hopkins Bayview Med Ctr, Behav Pharmacol Res Unit, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
dronabinol; plasma; cannabinoids; smoking; oral administration; ORAL THC; DELTA-9-TETRAHYDROCANNABINOL CONCENTRATIONS; TOBACCO WITHDRAWAL; MARIJUANA; SMOKING; BLOOD; DELTA(9)-TETRAHYDROCANNABINOL; ABSORPTION; THCCOOH; IMPACT;
D O I
10.1097/FTD.0b013e3182a5c446
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background:Recently, high-dose oral synthetic delta-9-tetrahydrocannabinol (THC) was shown to alleviate cannabis withdrawal symptoms. The present data describe cannabinoid pharmacokinetics in chronic, daily cannabis smokers who received high-dose oral THC pharmacotherapy and later a smoked cannabis challenge.Methods:Eleven daily cannabis smokers received 0, 30, 60, or 120 mg/d THC for four 5-day medication sessions, each separated by 9 days of ad libitum cannabis smoking. On the fifth day, participants were challenged with smoking one 5.9% THC cigarette. Plasma collected on the first and fifth days was quantified by two-dimensional gas chromatography mass spectrometer for THC, 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). Linear ranges (ng/mL) were 0.5-100 for THC, 1-50 for 11-OH-THC, and 0.5-200 for THCCOOH.Results:During placebo dosing, THC, 11-OH-THC, and THCCOOH concentrations consistently decreased, whereas all cannabinoids increased dose dependently during active dronabinol administration. THC increase over time was not significant after any dose, 11-OH-THC increased significantly during the 60- and 120-mg/d doses, and THCCOOH increased significantly only during the 120-mg/d dose. THC, 11-OH-THC, and THCCOOH concentrations peaked within 0.25 hours after cannabis smoking, except after 120 mg/d THC when THCCOOH peaked 0.5 hours before smoking.Conclusions:The significant withdrawal effects noted during placebo dronabinol administration were supported by significant plasma THC and 11-OH-THC concentration decreases. During active dronabinol dosing, significant dose-dependent increases in THC and 11-OH-THC concentrations support withdrawal symptom suppression. THC concentrations after cannabis smoking were only distinguishable from oral THC doses for 1 hour, too short a period to feasibly identify cannabis relapse. THCCOOH/THC ratios were higher 14 hours after overnight oral dronabinol abstinence but cannot distinguish oral THC dosing from the smoked cannabis intake.
引用
收藏
页码:218 / 224
页数:7
相关论文
共 50 条
  • [21] CANNABINOID CONCENTRATIONS IN PLASMA AFTER PASSIVE INHALATION OF MARIJUANA SMOKE
    MASON, AP
    PEREZREYES, M
    MCBAY, AJ
    FOLTZ, RL
    JOURNAL OF ANALYTICAL TOXICOLOGY, 1983, 7 (04) : 172 - 174
  • [22] METABOLISM OF CANNABIS .8. STABILITY, TRANSFER AND ABSORPTION OF CANNABINOID CONSTITUENTS OF CANNABIS (HASHISH) DURING SMOKING
    AGURELL, S
    LEANDER, K
    ACTA PHARMACEUTICA SUECICA, 1971, 8 (04): : 391 - &
  • [23] Cannabinoid concentrations in confiscated cannabis samples and in whole blood and urine after smoking CBD-rich cannabis as a “tobacco substitute”
    Marianne Hädener
    Tim J. Gelmi
    Marie Martin-Fabritius
    Wolfgang Weinmann
    Matthias Pfäffli
    International Journal of Legal Medicine, 2019, 133 : 821 - 832
  • [24] Cannabinoid concentrations in confiscated cannabis samples and in whole blood and urine after smoking CBD-rich cannabis as a "tobacco substitute"
    Hadener, Marianne
    Gelmi, Tim J.
    Martin-Fabritius, Marie
    Weinmann, Wolfgang
    Pfaffli, Matthias
    INTERNATIONAL JOURNAL OF LEGAL MEDICINE, 2019, 133 (03) : 821 - 832
  • [25] Cannabinoid receptor type 2 gene is associated with comorbidity of schizophrenia and cannabis dependence and fatty acid amide hydrolase gene is associated with cannabis dependence in the Spanish population
    Horcajadas, Francisco Arias
    Piriz, Jose Ramon Davila
    Gonzalez, Alba Parra
    Romero, Sergio Sanchez
    Sanchez-Morla, Eva
    Sanchez, Israel Ampuero
    Atance, Jose Antonio Ramos
    ADICCIONES, 2023, 35 (01) : 33 - 46
  • [26] Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers
    Sebastien Anizan
    Garry Milman
    Nathalie Desrosiers
    Allan J. Barnes
    David A. Gorelick
    Marilyn A. Huestis
    Analytical and Bioanalytical Chemistry, 2013, 405 : 8451 - 8461
  • [27] Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers
    Anizan, Sebastien
    Milman, Garry
    Desrosiers, Nathalie
    Barnes, Allan J.
    Gorelick, David A.
    Huestis, Marilyn A.
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2013, 405 (26) : 8451 - 8461
  • [28] Exercise increases plasma THC concentrations in regular cannabis users
    Wong, Alexander
    Montebello, Mark E.
    Norberg, Melissa M.
    Rooney, Kieron
    Lintzeris, Nicholas
    Bruno, Raimondo
    Booth, Jessica
    Arnold, Jonathon C.
    McGregor, Iain S.
    DRUG AND ALCOHOL DEPENDENCE, 2013, 133 (02) : 763 - 767
  • [29] The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence:: Preclinical evidence
    Colombo, Giancarlo
    Orru, Alessandro
    Lai, Paola
    Cabras, Claudia
    Maccioni, Paola
    Rubio, Marina
    Gessa, Gian Luigi
    Carai, Mauro A. M.
    MOLECULAR NEUROBIOLOGY, 2007, 36 (01) : 102 - 112
  • [30] The Cannabinoid CB1 Receptor Antagonist, Rimonabant, as a Promising Pharmacotherapy for Alcohol Dependence: Preclinical Evidence
    Giancarlo Colombo
    Alessandro Orrù
    Paola Lai
    Claudia Cabras
    Paola Maccioni
    Marina Rubio
    Gian Luigi Gessa
    Mauro A. M. Carai
    Molecular Neurobiology, 2007, 36 : 102 - 112